Ca\textsuperscript{2+}/Calmodulin-Dependent Protein Kinase II Regulation by RIPK3 Alleviates Necroptosis in Transverse Arch Constriction-Induced Heart Failure

Ji Cao\textsuperscript{1†}, Jingjing Zhang\textsuperscript{1,2†}, Jianan Qian\textsuperscript{1}, Xue Wang\textsuperscript{1}, Wei Zhang\textsuperscript{1,2*} and Xiangfan Chen\textsuperscript{3*}

\textsuperscript{1} School of Pharmacy, Nantong University, Nantong, China, \textsuperscript{2} School of Medicine, Nantong University, Nantong, China, \textsuperscript{3} Department of Pharmacy, Nantong First People's Hospital, The Second Affiliated Hospital of Nantong University, Nantong, China

INTRODUCTION

As a complex clinical syndrome, heart failure (HF) is caused by ventricular dysfunction or structural damage, leading to insufficient cardiac output, as well as the inability to meet the body's metabolic needs. Despite progress in recent years in treatment and prevention, HF is still the leading cause of incidence rate and mortality of cardiovascular diseases worldwide. About 40 million people suffer from HF globally (1). HF is pathologically characterized by myocardial stiffness, arrhythmia, myocardial fibrosis, and myocardial hypertrophy. The pathogenesis of HF may be attributed to...
many factors, while the most common risk factors are hypertension, coronary heart disease (heart artery obstruction), diabetes, obesity, smoking, and genetics (2, 3). However, effective therapeutic targets and approaches for HF are not well established. Therefore, it is urgently necessary to develop potential control strategies.

Recent studies have found a new type of apoptosis, namely necroptosis, morphologically different from apoptosis or necrosis (4). Necroptosis is mainly characterized by cell enlargement, swelling of organelles (especially mitochondria), rupture of the plasma membrane, cell disintegration, loss of integrity, and release of pro-inflammatory contents (5, 6). Receptor interacting protein kinase 3 (RIPK3) plays a crucial role in the signaling pathway of necroptosis. RIPK3 triggers necroptosis together with receptor-interacting protein 1 (RIPK1) and mixed line kinase domain-like protein (MLKL) (7, 8). In addition, studies have found that Ca$^{2+}$/calmodulin-dependent protein kinase (CaMKII) is a new substrate of RIPK3-mediated myocardial necroptosis caused by ischemia and oxidative stress (9). Furthermore, new evidence has confirmed that necroptosis plays a vital role in cardiovascular disease (10). CaMKII is a serine/threonine-specific phosphokinase with multiple functions, including critical proteins regulating Ca$^{2+}$ treatment, intercellular coupling, cell death, inflammation, and mitochondrial function (11–13). CaMKII can be activated by binding to calcium bound calmodulin (Ca$^{2+}$/CAM), autophosphorylation, oxidation, S-nitrosylation, and o-glutamate acylation (14–17). The activation of CaMKII mediates the physiological or pathological response and remodeling under cardiac stress. Studies have shown that continuous CaMKII activation plays a vital role in HF (18, 19), myocardial hypertrophy (20), arrhythmia (21), and myocardial infarction (22). In recent years, some studies have revealed the potential role of CaMKII in HF (23). Therefore, clarifying the mechanism of CaMKII may help provide new pharmacological targets for HF.

CaMKII has four subtypes: α, β, γ, and δ. CaMKIIδ is particularly important in the heart. There are three isoforms of CaMKIIδ resulting from the alternative splicing of exons 14, 15, and 16 of its pre-mRNA, CaMKIIδA, CaMKIIδB, and CaMKIIδC. CaMKIIδ alternative splicing is strictly regulated. Once disorder occurs, the expressions of the three variants become unbalanced, resulting in cardiomyocyte dysfunction and eventually heart disease (24).

RIPK3 is a serine/threonine kinase mainly present in the heart. It activates CaMKII through phosphorylation and/or oxidation, triggering mitochondrial permeability transition pore (MPTPP) opening and myocardial necroptosis (9). Studies have shown that the expression of RIPK3 is elevated in HF patients (25). However, the clinical value of RIPK3 remains largely undetermined.

In the present study, we investigated the effect of CaMKII on necroptosis in the development of HF and its molecular mechanism. In addition, we also explored the regulatory effect of RIPK3 on CaMKIIδ alternative splicing and CaMKII activity to ameliorate transverse arch constriction (TAC)-induced myocardial necroptosis in wild type (WT) and RIPK3−/− mice with HF.

### MATERIALS AND METHODS

#### Animals

Wild type C57BL/6 mice (male, 8 weeks old) were provided by the Experimental Animal Center of Nantong University (Nantong, China). RIPK3−/− mice were donated by the Institute of Molecular Medicine, Peking University (Beijing, China). The animals were housed in the Experimental Animal Center of Nantong University at 20°C with a 12-h light/dark cycle, and the mice were fed a standard laboratory diet and tap water. All animal-related procedures complied with the recommendations of the “Guidelines for the Care and Use of Laboratory Animals” (approval number: NTU-20161225) issued by the National Institutes of Health and the Animal Care and Use Steering Committee of Nantong University.

#### Establishment of Heart Failure Mouse Model

Mice were randomly divided into WT mice group (WT), WT mice receiving TAC (26) treatment group (WT + TAC), RIPK3−/− mice group (RIPK3−/−), and RIPK3−/− mice receiving TAC treatment group (RIPK3−/− + TAC). After 1 week of adaptive feeding, the mice in the model group underwent TAC after overnight food deprivation. Briefly, the mice were intraperitoneally injected with chloral hydrate and depilated after anesthesia. First, the neck skin was cut along the midline, followed by intubation. Next, the sternum was cut to expose the thymus, the thymus was separated, and then the aortic arch was identified and narrowed with a 28-g needle. The mice in the control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks.

#### Tail Vein Injection of Adeno-Associated Virus

To evaluate the role of RIPK3 in HF, male C57BL/6 mice (8 weeks old) were transfected with Adeno-Associated Virus (AAV)-vector and AAV-RIPK3 shRNAs through the tail vein. The injection dose was 1 × 10^{11}vg per mouse once, and then TAC operation was performed to establish a mouse model of HF. The operation method was the same as those mentioned above. In addition, all groups of mice were given continuous feeding for 6 weeks.

#### Echocardiography

At 6 weeks after the operation, the mice were anesthetized with 1.5% isoflurane, the left chest hair was removed, and the heart geometry was measured at a probe frequency of 30 MHz from the parasternal long-axis view using a small animal color ultrasonic diagnostic device. The cardiac morphology and function were examined by two-dimensional guided M-mode echocardiography (visual sonic VEVO 2100, Toronto, ON, Canada). The thickness of the interventricular septum (IVS) and left ventricle posterior wall (LV PW) was determined. Subsequently, the ejection fraction (EF) and LV fractional shortening (FS) were calculated based on the average of 10 cardiac cycles. All indexes were measured three times in a row.
Hematoxylin and Eosin Staining
The left ventricles were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and then cut into 5-μm sections. The sections were subjected to Hematoxylin and Eosin (H&E) staining and dehydrated with ethanol. Subsequently, the sections were observed and photographed under an optical microscope.

TdT-Mediated dUTP Nick-End Labeling Staining
The left ventricles were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and then cut into 5-μm sections. After staining with TdT-Mediated dUTP Nick-End Labeling (TUNEL) (Beyotime, Shanghai, China) at 37°C for 60 min, the sections were washed three times with PBS, then observed, and photographed under an optical microscope. The quantification was performed using ImageJ software.

Sirius Red Staining
The left ventricles were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and then cut into 5-μm sections. The paraffin-embedded sections were deparaffinized in water, chromated with potassium dichromate overnight, stained with iron hematoxylin, ponceau acid fuchsin, phosphomolybdic acid, and aniline blue sequentially, then dehydrated, mounted, and photographed under a microscope.

Masson Staining
The left ventricles were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and then cut into 5-μm sections. The paraffin-embedded sections were deparaffinized in water, chopped with potassium dichromate overnight, stained with iron hematoxylin, ponceau acid fuchsin, phosphomolybdic acid, and aniline blue sequentially, then dehydrated, mounted, and examined under a microscope.

WGA Staining
The left ventricles were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and then cut into 5-μm sections. Next, the paraffin-embedded sections were deparaffinized in water. After antigen retrieval, the WGA working solution was added dropwise, followed by incubation for 30 min. Subsequently, the sections were stained for nuclear mounting and examined under a microscope.

Determination of Blood Biochemical Indexes
Before sacrifice, whole blood was collected from the orbital vein of each mouse and centrifuged at 3,000 g for 20 min. Serum was kept at −80°C for further analyses. Corresponding commercial kits were used to detect the lactate dehydrogenase (LDH) activity and the contents of creatine kinase (CK), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in mouse serum.

Measurement of Superoxide Formation
Superoxide production in myocardial tissue was detected using dihydroethidium (DHE) staining under a fluorescence microscope. Briefly, myocardial tissue sections (5 μm) were prepared and then incubated (30 min, 37°C) in Krebs-HEPES buffer (mM components: NaCl 99, KCl 4.7, MgSO4 1.2, KH2PO4 1.0, CaCl2 1.9, NaHCO3 25, glucose 11.1, Na HEPES 20; pH 7.4) containing 2 μM DHE in a dark room. The slides were examined with a Nikon TE2000 inverted microscope (Nikon, Tokyo, Japan) at excitation and emission wavelengths of 480 and 610 nm, respectively.

The thiobarbituric acid method (Beyotime) was used to detect the level of malondialdehyde (MDA) in the myocardium. The total antioxidant capacity (T-AOC) of the myocardium was measured by the T-AOC detection kit using the plasma iron reduction capacity method (Beyotime). The activities of total superoxide dismutase (SOD) in the myocardium were determined using the WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2 Htetrazole) method (Beyotime).

Ultrastructural Observation of Myocardium
The fresh myocardia were cut into three pieces (1 mm) and fixed with 4% glutaraldehyde and 1% osmium acid. The samples were dehydrated with acetone, embedded in Epon812, stained with toluidine blue, cut into 70-nm sections, and stained with uranyl acetate and lead citrate. A transmission electron microscope (JEM-1230) was used to examine the ultrastructure of myocardial tissue. A visible image consisting of 15 randomly selected areas per slice was taken to determine the structure and number of mitochondria. The volume of mitochondria was calculated, and the number of mitochondria was counted.

Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from myocardial tissue using Trizol reagent (Takara, Kyoto, Japan), and then the purified RNA was reversely transcribed into cDNA using PrimeScript™ RT Master Mix Kit (Takara). SYBR Green Fast qPCR mix (Takara, United States) was used to perform Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). 18S was used as a housekeeping gene. Each experiment was performed in triplicate. The relative expressions of target genes were calculated using the 2−ΔΔCt method.

Western Blotting Analysis
The proteins extracted from the myocardial tissue were subjected to SDS-PAGE and transferred onto the PVDF membranes (Millipore, Billerica, MA, United States). After blocking with TBST buffer (Tris-HCl 10 mmol-L-1, NaCl 120 mmol-L-1, Tween-20 0.1%; pH 7.4) containing 5% skimmed milk (v/v) at room temperature for 2 h, the membranes were incubated with primary antibodies at 4°C overnight, including anti-ANP (1:1,000, Abcam, Cambridge, United Kingdom), anti-BNP (1:1,000, Abcam, Cambridge, United Kingdom), anti-ox-CaMKII (1: 1,000, Millipore, Kenilworth, NJ, United States), anti-CaMKII (1: 1,000, Abcam, Cambridge, United Kingdom), anti-caspase 3, anti-cleaved...
caspase 3, anti-MLKL, anti-p-MLKL, and anti-RIPK1 (1: 1,000, Cell Signaling Technology, Danvers, MA, United States); anti-p-CaMKII (1: 1,000, Thermo Fisher Scientific, Rockford, IL, United States), anti-GAPDH (1: 5,000, Sigma-Aldrich, St. Louis, MO, United States), and anti-β-tubulin. Subsequently, the blots were incubated with horseradish peroxidase (HRP-) conjugated secondary antibody at room temperature for 1.5 h. The immunoreactive bands were visualized by enhanced chemiluminescence (ECL) (Thermo Fisher Scientific, Rockford, IL, United States). GAPDH or β-tubulin was used as the loading control.

**Statistical Analysis**

All data were expressed as mean ± standard error (SEM). Comparisons between two groups were conducted by the unpaired Student’s t-test. One-way analysis of variance analysis (ANOVA) and Student-Newman-Keuls (SNK) test statistics were used for comparisons among multiple groups. P < 0.05 was considered statistically significant.

**RESULTS**

**Cardiac Dysfunction, CaMKIIδ Alternative Splicing Disorder, and Enhancement of Apoptosis in Heart Failure Mice**

Echocardiography showed that compared with the control group, HF mice had diastolic and systolic dysfunctions, the levels of EF, FS, and E/A were decreased (Figures 1A–C), and the expressions of hypertrophy and HF indexes ANP and BNP were significantly increased (Figures 1D,E), indicating that an HF model was successfully established in this study. CaMKIIδ alternative splicing disorder easily promotes cardiomyocyte dysfunction and ultimately leads to heart disease (27). Since there is no specific antibody for CaMKIIδ splice variants, qRT-PCR was used to detect the expressions of CaMKIIδ A, CaMKIIδ B, and CaMKIIδ C at the mRNA level. In HF mice, the expressions of CaMKIIδ A and CaMKIIδ B were significantly decreased, while the expression of CaMKIIδ C was significantly increased (Figure 1H), indicating CaMKIIδ alternative splicing disorder in HF mice. In addition, the oxidation and phosphorylation of CaMKII were also increased in the HF group (Figures 1F,G). Several studies have shown that RIPK3 is involved in necroptosis. Our study confirmed that RIPK3 was significantly increased in the heart of HF mice (Figure 2A). Meanwhile, the expression of RIPK1 downstream of RIPK3 and the phosphorylation of MLKL were also up-regulated in the myocardium of HF mice (Figures 2B,C). Necroptosis is a particular form of cell death. TUNEL staining and the expression of cleaved-caspase 3 (Figures 2D–F) showed significantly more apoptotic cardiomyocytes in HF mice compared with the control group. All these data showed that cardiac dysfunction, CaMKIIδ activity, alternative splicing disorder, and apoptosis were enhanced in HF mice.

**RIPK3 Deficiency Can Reduce Cardiac Dysfunction, Myocardial Injury, Myocardial Fibrosis, and Inflammatory Response in Heart Failure**

We used RIPK3−/− mice to verify the role of RIPK3 in the development of HF. Echocardiography showed that depletion of RIPK3 significantly increased EF and FS in HF mice compared with the control group (Figures 3A–C), indicating that systolic and diastolic functions were improved. By detecting the expressions of ANP and BNP at the protein level, we found that depletion of RIPK3 had no significant effect on hypertrophy and expressions of HF genes in HF mice (Figures 3D,E). The cross-sectional area of mouse cardiomyocytes was determined by WGA staining, indicating that cardiomyocytes of WT and RIPK3−/− mice were significantly enlarged after TAC operation, and depletion of RIPK3 could significantly reduce the size of cardiomyocytes (Figures 4A,B). H&E staining showed that depletion of RIPK3 could reduce the distortion and disorder of cardiomyocytes in HF mice (Figures 4C,D). To evaluate the degree of myocardial fibrosis in mice, we applied Sirius red staining (Figures 5A,B) and Masson staining (Figures 5C,D). The results showed that depletion of RIPK3 significantly improved the degree of collagen deposition and myocardial fibrosis. After TAC operation, the serum LDH and CK levels of RIPK3−/− mice were significantly lower compared with WT mice (Figures 6D,E). Depletion of RIPK3 improved the degree of myocardial injury in HF mice. Moreover, we found that the inflammatory level was significantly decreased in the myocardial tissue in the RIPK3−/− + TAC group (Figures 6E,G), indicating that the myocardial injury was improved to a certain extent. These data suggested that although depletion of RIPK3 could not significantly inhibit the occurrence and development of HF, it could significantly ameliorate the central dysfunction, myocardial injury, myocardial fibrosis, and inflammatory response in HF.

**Loss of RIPK3 Can Reduce RIPK1 Expression, MLKL Phosphorylation, Necroptosis, CaMKII Activity, and CaMKIIδ Alternative Splicing Disorder in Heart Failure Mice and Improve Oxidative Stress and Myocardial Mitochondrial Ultrastructure**

Our results showed that depletion of RIPK3 could reduce the oxidation and phosphorylation of CaMKII in the myocardium of HF mice (Figures 6A,B). The expression of CaMKIIδ was detected by qRT-PCR. We found that depletion of RIPK3 improved CaMKIIδ alternative splicing disorder to some extent (Figure 6C), which alleviated cardiomyocyte disorder. In addition to RIPK3, studies have shown that RIPK1 is also involved in necroptosis, and the phosphorylation of MLKL is an essential effector molecule of necroptosis (28). In the present study, the expression of RIPK3 was significantly increased in the myocardium of HF mice (Figure 7A), while the RIPK1 expression was...
Cardiac dysfunction, increased expressions of ANP and BNP, CaMKII alternative splicing disorder, CaMKII oxidation, and phosphorylation levels are increased in HF mice. Male 8-week-old C57BL/6 mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) Echocardiography. (B) EF and FS. (C) IVS and LVPW. (D) The expression of ANP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control; (E) The expression of BNP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (F) Western blotting analysis was used to detect the expression of OX-CaMKII protein in myocardial tissue, and GAPDH was used as loading control; (G) Western blotting was used to detect the expression of P-CaMKII protein in myocardial tissue, and GAPDH was used as a loading control. (H) Detection of myocardial CaMKII A, CaMKII B, and CaMKII C at the mRNA level by qRT-PCR, and 18S was used as the housekeeping gene. Compared with the WT + sham group, **P < 0.01 and *P < 0.05. n = 6.

FIGURE 1

expression and MLKL phosphorylation were also increased. However, the RIPK1 expression and MLKL phosphorylation were reduced in RIPK3−/− HF mice (Figures 7B, C). TUNEL staining and the expression of cleaved caspase 3 (Figures 7D–F) showed that apoptosis was significantly improved in RIPK3−/− HF mice. In addition, oxidative stress plays an essential role in the
FIGURE 2 | The expressions of RIPK3 and RIPK1, as well as the levels of MLKL phosphorylation and apoptosis, are increased in HF mice. Male 8-week-old C57BL/6 mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The expression of RIPK3 at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (B) The expression of RIPK1 at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (C) The levels of MLKL and P-MLKL proteins in myocardial tissue were detected by Western blotting analysis, and GAPDH was used as a loading control. (D) The level of apoptosis in myocardial tissue was measured by TUNEL staining, bar = 50 µm; (E) The statistical chart of TUNEL-positive cells. (F) The levels of cleaved caspase 3 and caspase 3 in myocardial tissue were detected by Western blotting analysis, and β-tubulin was used as a loading control. Compared with WT + sham group, *P < 0.05, n = 6.
FIGURE 3 | Depletion of RIPK3 can alleviate cardiac insufficiency in mice with HF and has no significant improvement in the increased expressions of ANP and BNP. Male 8-week-old WT and RIPK3−/− mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) Echocardiography. (B) EF and FS. (C) IVS and LVPW. (D) The expression of ANP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (E) The expression of BNP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. Compared with WT + sham group, **P < 0.01; compared with RIPK3−/− + sham group, ***P < 0.01 and ##P < 0.05; compared with WT + TAC group, &&P < 0.01 and &P < 0.05. n = 6.
Depletion of RIPK3 can inhibit the increase of cardiomyocyte cross-sectional area in mice with HF and improve myocardial injury. Male 8-week-old WT and RIPK3\(^{-/-}\) mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The cross-sectional area of mouse cardiomyocytes was observed by WGA staining, bar = 50 \(\mu\)m. (B) Cell area measurements in WGA. (C) Tissue damage area measurements in H&E. (D) H&E staining was used to detect the degree of myocardial injury, bar = 50 \(\mu\)m. Compared with WT + sham group, **\(P < 0.01\); compared with RIPK3\(^{-/-}\) + sham group, ##\(P < 0.01\); compared with WT + TAC group, &&\(P < 0.01\). n = 6.
occurrence and development of heart disease. Reactive oxygen species (ROS) accumulation is the main factor in myocardial necrosis, which may reduce the survival of myocardial cells and aggravate myocardial damage. We selected MDA, T-AOC, and T-SOD kits to evaluate the AOC of mouse myocardial tissue, and the results showed that the myocardial tissue’s ability to scavenge oxygen free radicals was enhanced in RIPK3−/− mice, and the accumulation of ROS was decreased (Figures 7G–I). We used DHE staining to evaluate the level of ROS in tissues. We found that at 6 weeks after the TAC surgery, the red fluorescence intensity of myocardial tissue in WT mice was increased, while the red fluorescence intensity of myocardial tissue in RIPK3−/− mice was weaker compared with WT mice, indicating that depletion of RIPK3 reduced the accumulation of ROS in myocardial tissue (Figures 8A,B). The ultrastructure of myocardial mitochondria in the left ventricle of mice with myocardial hypertrophy was observed by a transmission electron microscope. However, in contrast to WT and RIPK3−/− mice without TAC, mitochondria in the RIPK3−/− + TAC group were relatively intact and began to exhibit cristae fragmentation, which was much improved compared with the WT + TAC group (Figures 8C,D).

AAV-RIPK3 shRNA Interferes With the Expression of RIPK3, Reverses the Dysfunction of Myocardial Hypertrophy, Myocardial Fibrosis, and Inflammation, and Reduces Myocardial Damage

To further evaluate the relative role of RIPK3 in myocardial hypertrophy, we injected recombinant AAV-carrying RIPK3 shRNA directly into the tail vein of mice to interfere with...
FIGURE 6 | Depletion of RIPK3 can alleviate the elevated levels of CaMKII oxidation and phosphorylation, improve the CaMKII alternative splicing disorder in HF mice and the degree of myocardial injury and inflammatory response. Male 8-week-old WT and RIPK3−/− mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The expression of OX-CaMKII at the protein level in myocardial tissue was detected by Western blotting analysis, and GAPDH was used as a loading control. (B) The expression of P-CaMKII at the protein level in myocardial tissue was detected by Western blotting analysis, and GAPDH was used as a loading control. (C) Detection of myocardial CaMKII A, CaMKII B, and CaMKII C at the mRNA level by qRT-PCR, and 18S was used as the housekeeping gene. (D) The levels of serum LDH, CK, IL-6, and TNF-α. Compared with WT + sham group, *P < 0.01; compared with RIPK3−/− + sham group, #P < 0.01 and ##P < 0.05; compared with WT + TAC group, &&P < 0.01 and &P < 0.05. n = 6.
Depletion of RIPK3 can reduce the expressions of RIPK3 and RIPK1, as well as the MLKL phosphorylation level and cardiomyocyte apoptosis in HF mice and improve antioxidant capacity. Male 8-week-old WT and RIPK3−/− mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The expression of RIPK3 at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (B) Western blotting analysis was used to detect the expression of RIPK1 at the protein level in myocardial tissue, and GAPDH was used as a loading control. (C) Western blotting analysis was used to detect the expressions of MLKL and P-MLKL at the protein level in myocardial tissue, and GAPDH was used as a loading control. (D) The expressions of cleaved caspase 3 and caspase 3 at the protein level in myocardial tissue were detected by Western blotting analysis, and β-tubulin was used as a loading control. (E) TUNEL staining was used to determine the level of apoptosis in myocardial tissue, bar = 50 µm. (F) The statistical chart of TUNEL-positive cells. (G) The levels of serum MDA, (H) T-AOC, and (I) SOD. Compared with WT + sham group, **P < 0.01; compared with RIPK3−/− + sham group, ##P < 0.01 and #P < 0.05; compared with WT + TAC group, &&P < 0.01 and &P < 0.05; n = 6.
Depletion of RIPK3 can reduce ROS accumulation in myocardial tissue of HF mice and improve antioxidant capacity and mitochondrial structural abnormalities. Male 8-week-old WT and RIPK3<sup>−/−</sup> mice were treated with TAC using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) DHE staining, bar = 50 µm. (B) Average fluorescence intensity measurements of DHE. (C) Mitochondrial damage area. (D) The ultrastructure of LV mitochondria was observed by transmission electron microscope, bar = 2 µm. Lower picture bar = 0.5 µm. Compared with WT + sham group, **P < 0.01; compared with RIPK3<sup>−/−</sup> + sham group, ##P < 0.01; compared with WT + TAC group, &&P < 0.01. n = 6.

the expression of RIPK3. TAC operation was performed on the pretreated mice, and the control group received sham surgery. Echocardiography showed no significant changes in IVS and LVPW in HF mice after interfering with the expression of RIPK3, while the EF and FS values of this group were increased significantly (Figures 9A–C), suggesting that the
Interference with RIPK3 can alleviate cardiac insufficiency in HF mice and has no significant improvement in the up-regulation of ANP and BNP. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) Echocardiography. (B) EF and FS. (C) IVS and LVPW. (D) The expression of ANP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (E) The expression of BNP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. Compared with WT + sham group, **P < 0.01 and *P < 0.05; compared with WT + TAC group, #P < 0.05; compared with WT + AAV-vector group, &P < 0.05. n = 6.

FIGURE 9 | Interference with RIPK3 can alleviate cardiac insufficiency in HF mice and has no significant improvement in the up-regulation of ANP and BNP. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) Echocardiography. (B) EF and FS. (C) IVS and LVPW. (D) The expression of ANP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (E) The expression of BNP at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. Compared with WT + sham group, **P < 0.01 and *P < 0.05; compared with WT + TAC group, #P < 0.05; compared with WT + AAV-vector group, &P < 0.05. n = 6.

systolic cardiac function was improved. The expressions of hypertrophy and HF-related genes (ANP and BNP) in TAC-treated mice were increased significantly (Figures 9D,E). In addition, the cross-sectional area of cardiomyocytes in the model group was increased significantly, while the model group interfered with AAV-RIPK3 shRNA was improved significantly.
of RIPK3, RIPK1, and P-MLKL, which mediate necroptosis, were revealed severe apoptosis in HF mice. Meanwhile, the expressions study, TUNEL staining and the expression of cleaved caspase 3. Necroptosis is a particular form of apoptosis. In our present injury (IRI), myocardial infarction, and cardiac remodeling (28). prevention and treatment methods remain very limited (29). The rate and mortality rate of HF are high worldwide, while the ANP and BNP were increased in HF mice. The incidence the E/A was significantly decreased, and the expressions of fibrosis, arrhythmia, and hypertrophy. Our results showed that the expressions of RIPK3 and downstream RIPK1 and P-MLKL, and triggers necroptosis (5, 30). Excessive necroptosis can lead to embryo death (31) and a variety of heart diseases, including but not limited to myocardial infarction, IRI, and HF (32). MLKL is a pseudokinase produced by RIPK1 binding and phosphorylating RIPK3, and then phosphorylated RIPK3 undergoes further phosphorylation, which is called MLKL (33). Then, phosphorylated MLKL (P-MLKL) is transferred to the plasma membrane and oligomerized to form pores on the cell membrane, thereby increasing the permeability of the cell membrane (34) and leading to cell expansion and final rupture (35). Recent studies have shown that necrotic bodies formed by RIPK3 and P-MLKL oligomers are essential for necroptosis (36). Our results showed that the RIPK1 expression and MLKL phosphorylation were significantly up-regulated in the myocardium of HF mice, indicating the existence of necroptosis, and MLKL pathway might be the downstream or substrate of RIPK3-mediated necroptosis. This finding was significantly alleviated in RIPK3−/− mice with HF. Moreover, this was also confirmed in AAV-RIPK3-shRNA infected mice. However, the specific pathway of RIPK3-induced myocardial necroptosis is still unclear.

Caspases are a group of cysteine proteases that can regulate apoptosis. Caspases cleave substrates at the carboxyl end of specific aspartic acid residues. These proteases usually exist in healthy cells as inactive enzymes, and they will be activated by autolytic division when stimulated. These enzymes then cleave the substrate at one or two specific sites, leading to the activation, inactivation, relocation, or remodeling of the substrate (37). The activation of caspase 3 is necessary for most morphological and biochemical events related to apoptosis (38, 39), and caspase 3 is responsible for most protein hydrolysis in apoptosis (40). The cleavage of caspase 3 is usually considered a universal marker of apoptosis. Our study found that the expression of cleaved caspase 3 was increased significantly in the heart tissue of HF mice, suggesting apoptosis. As mentioned above, the expressions of RIPK3 and downstream RIPK1 and P-MLKL, which mediate necroptosis, were increased, and necroptosis is a particular type of apoptosis. Therefore, we believed that the apoptosis here was necroptosis. In RIPK3−/− mice with HF, the expression of cleaved caspase 3 was significantly lower compared with the control group, and the same result was observed in AAV-RIPK3-shRNA-infected mice, indicating that depletion or inhibition of RIPK3 could effectively reduce the occurrence of myocardial necroptosis.

CaMKII is a pleiotropic signal molecule that regulates gene expression, contraction, metabolism, ROS, Ca²⁺ homeostasis,
Interference with RIPK3 can inhibit the increase of cardiomyocyte cross-sectional area in HF mice and alleviate myocardial injury. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The cross-sectional area of mouse cardiomyocytes was observed by WGA staining, bar = 50 µm. (B) Cell area measurements in WGA staining. (C) Tissue damage area measurements in H&E staining. (D) H&E staining was used to detect the degree of myocardial injury, bar = 50 µm. Compared with WT + sham group, **P < 0.01; compared with WT + TAC group, ##P < 0.01; compared with WT + AAV-vector group, ###P < 0.01. n = 6.
and inflammatory response of cardiomyocytes (41). CaMKII is inactivated under basal conditions. Continuous activation of CaMKII can promote cardiomyocyte death under endoplasmic reticulum (ER) stress, hyperglycemia, and IRI (42–44). It has been found that RIPK3 leads to myocardial necroptosis through oxidation and phosphorylation of CaMKII after IRI or adriamycin stimulation (9). Our study found that the phosphorylation and oxidation of CaMKII were significantly enhanced in cardiomyocytes of HF mice, while such up-regulation was significantly reversed in RIPK3−/− and AAV-RIPK3-shRNA-infected mice. In conclusion, CaMKII signaling pathway might be the downstream or substrate of RIPK3-mediated myocardial injury and necroptosis in HF.

Many studies have confirmed that mitochondrial dysfunction is closely related to necroptosis. Mitochondria are the primary source of energy and ROS production, and mitochondrial dysfunction leads to excessive ROS production and cell death (45). Up-regulation of RIPK3 induces ER stress, accompanied by increased intracellular Ca2+ level and xanthine oxidase (XO) expression. Activated XO increases cellular ROS that mediates MPTP opening and cardiomyocyte necroptosis (46). Our study found that depletion or inhibition of RIPK3 improved the ultrastructure of myocardial mitochondria in HF mice. These results emphasized that mitochondrial damage might be the underlying mechanism of RIPK3-induced necroptosis in HF.

In conclusion, our study supported the presence of severe necroptosis in HF. Depletion or inhibition of RIPK3 could reduce myocardial injury, improve cardiac function, inhibit CaMKII activation, regulate CaMKIIδ alternative splicing disorder, down-regulate the expression of P-MLKL, and attenuate necroptosis, inflammatory response, and oxidative stress in HF mice. Collectively, myocardial

FIGURE 11 | Interference with RIPK3 can improve the degree of collagen deposition and myocardial fibrosis in HF mice. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) Sirius red staining, bar = 50 µm. (B) Sirius red staining area measurements. (C) Masson staining area measurements. (D) Masson staining, bar = 50 µm. Compared with WT + sham group, **P < 0.01; compared with WT + TAC group, ##P < 0.01; compared with WT + AAV-vector group, &&P < 0.01. n = 6.
FIGURE 12 | Interference with RIPK3 can alleviate the elevated levels of CaMKII oxidation and phosphorylation, improve CaMKII alternative splicing disorder, the degree of myocardial injury, and inflammatory response in HF mice. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The expression of OX-CaMKII at the protein level in myocardial tissue was detected by Western blotting analysis, and GAPDH was used as a loading control. (B) The expression of P-CaMKII at the protein level in myocardial tissue was detected by Western blotting analysis, and GAPDH was used as a loading control. (C) Detection of myocardial CaMKII A, CaMKII B, and CaMKII C at the mRNA level by qRT-PCR, and 18S was used as the housekeeping gene. (D) The levels of serum LDH, (E) CK, (F) IL-6, and (G) TNF-α. Compared with WT + sham group, **P < 0.01; compared with WT + TAC group, ##P < 0.01 and #P < 0.05; compared with WT + AAV-vector group, &&P < 0.01 and &P < 0.05. n = 6.
FIGURE 13 | Interference with RIPK3 can alleviate the up-regulation of RIPK3 and RIPK1, as well as the MLKL phosphorylation, reduce cardiomyocyte necroptosis, and improve antioxidant capacity in HF mice. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) The expression of RIPK3 at the protein level in myocardial tissue was detected by Western blotting analysis, and β-tubulin was used as a loading control. (B) The expression of RIPK1 at the protein level in myocardial tissue was detected by Western blotting analysis, and GAPDH was used as a loading control. (C) The expressions of MLKL and P-MLKL at the protein level in myocardial tissue were detected by Western blotting analysis, and GAPDH was used as a loading control. (D) The level of apoptosis in myocardial tissue was measured by TUNEL staining, bar = 50 µm. (E) The statistical chart of TUNEL-positive cells. (F) The expressions of cleaved caspase 3 and caspase 3 at the protein level in myocardial tissue were detected by Western blotting analysis, and β-tubulin was used as a loading control. (G) The levels of serum MDA, (H) T-AOC, (I) and SOD. Compared with WT + sham group, **P < 0.01; compared with WT + TAC group, ##P < 0.01 and #P < 0.05; compared with WT + AAV-vector group, &&P < 0.01 and &P < 0.05, n = 6.
FIGURE 14 | Interference with RIPK3 can reduce ROS accumulation in myocardial tissue of HF mice and improve antioxidant capacity and mitochondrial structural abnormalities. Male 8-week-old WT mice were pretreated with AAV-vector and AAV-shRNA through the tail vein, and TAC was performed using a 28-g needle. The control group received sham surgery. All groups of mice were given continuous feeding for 6 weeks. Hearts were then obtained for correlative testing. (A) DHE staining, bar = 50 µm. (B) The average fluorescence intensity measurements of DHE staining. (C) Mitochondrial damage area. (D) The ultrastructure of LV mitochondria was observed by transmission electron microscope, bar = 2 µm. Lower picture bar = 0.5 µm. Compared with WT + Sham group, **P < 0.01; compared with WT + TAC group, ##P < 0.01; compared with WT + AAV-vector group, &&P < 0.01. n = 6.
injury and necroptosis caused by activation of CaMKII and MLKL were increased in HF in a RIPK3-dependent manner. These findings provided valuable insights into the pathological process and mechanism of HF and offered new treatment strategies for HF.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The animal study was reviewed and approved by all procedures directed to the corresponding authors.

**REFERENCES**

1. Baman JR, Ahmad FS. Heart failure. *Jama.* (2020) 324:1015.
2. Slivnick J, Lampert BC. Hypertension and heart failure. *Heart Fail Clin.* (2019) 15:531–41. doi: 10.1016/j.hfc.2019.06.007
3. Pagliaro BR, Cannata F, Stefani GG, Bolognese L. Myocardial ischemia and coronary disease in heart failure. *Heart Fail Rev.* (2020) 25:53–65. doi: 10.1007/s10741-019-09831-z
4. Khoury MK, Gupta K, Franco SR, Liu B. Necroptosis in the pathophysiology of disease. *Am J Pathol.* (2020) 190:272–85. doi: 10.1016/j.ajpath.2019.10.012
5. Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L, et al. RIPK1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (review). *Int J Mol Med.* (2019) 44:771–86. doi: 10.3892/ijmm.2019.4244
6. Dhuriya YK, Sharma D. Necroptosis: a regulated inflammatory mode of cell death. *J Neuroinflammation.* (2018) 15:199. doi: 10.1186/s12974-018-1235-0
7. Wegner KW, Saleh D, Degtarev A. Complex pathologic roles of RIPK1 and RIPK3: moving beyond necroptosis. *Trends Pharmacol Sci.* (2017) 38:202–25. doi: 10.1016/j.tips.2016.12.005
8. Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. *Cell Death Dis.* (2021) 12:339. doi: 10.1038/s41419-021-03614-x
9. Zhang T, Zhang Y, Cui M, Jin L, Wang Y, Lv F, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. *Nat Med.* (2016) 22:175–82. doi: 10.1038/nm.4017
10. Gupta K, Phan N, Wang Q, Liu B. Necroptosis in cardiovascular disease – a new therapeutic target. *J Mol Cell Cardiol.* (2018) 118:26–35. doi: 10.1016/j.yjmcc.2018.03.003
11. Luczak ED, Wu Y, Granger JM, Joiner MA, Wilson NR, Gupta A, et al. Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy. *Nat Commun.* (2020) 11:4416. doi: 10.1038/s41467-020-18165-6
12. Rusciano MR, Sommariva E, Douin-Echnard V, Ciccarelli M, Poggi P, Maione AS. CaMKII activity in the inflammatory response of cardiac diseases. *Int J Mol Sci.* (2020) 21:4374. doi: 10.3390/ijms20184374
13. Feng N, Anderson ME. CaMKII is a nodal signal for multiple programmed cell death pathways in heart. *J Mol Cell Cardiol.* (2017) 103:102–9. doi: 10.1016/j.yjmcc.2016.12.007
14. Veitch CR, Power AS, Erickson JR. CaMKII inhibition is a novel therapeutic strategy to prevent diabetic cardiomyopathy. *Front Pharmacol.* (2021) 12:695401. doi: 10.3389/fphar.2021.695401
15. Hegyi B, Bers DM, Bossuyt J. CaMKII signaling in heart diseases: emerging role in diabetic cardiomyopathy. *J Mol Cell Cardiol.* (2019) 127:246–59. doi: 10.1016/j.yjmcc.2019.01.001
16. Qu J, Mei Q, Niu R. Oxidative CaMKII as a potential target for inflammatory disease (review). *Mol Med Rep.* (2019) 20:863–70. doi: 10.3892/mmr.2019.10309
17. Mesubi OO, Rokita AG, Abrol N, Wu Y, Chen B, Wang Q, et al. Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. *J Clin Invest.* (2021) 131:e95747. doi: 10.1172/JCI95747
18. Trum M, Wagner S, Maier LS, Mustroph J. CaMKII and GLUT1 in heart failure and the role of gliblozins. *Biochim Biophys Acta Mol Basis Dis.* (2020) 1866:165729. doi: 10.1016/j.bbadis.2020.165729
19. Pyun JH, Kim HJ, Jeong MH, Ahn BY, Vuong TA, Lee DI, et al. Cardiac specific PRMT1 ablation causes heart failure through CaMKII dysregulation. *Nat Commun.* (2018) 9:5107. doi: 10.1038/s41467-018-7606-y
20. Ljubojevic-Holzer S, Herren AW, Djalinac N, Moglicher J, Morotti S, Holzer M, et al. CaMKII-driven cardiac diseases: a matter of pathophysiological mechanisms. *Cardiovasc Res.* (2019) 115:1831–9. doi: 10.1093/cvr/cvx077
21. Mustroph J, Nef S, Maier LS. CaMKII as a target for arrhythmia suppression. *Pharmacol Ther.* (2017) 176:22–31. doi: 10.1016/j.pharmthera.2016.10.006
22. Liu T, Wang Q, Yao K. Huoxue wentong formula ameliorates myocardial infarction in rats through inhibiting CaMKII oxidation and phosphorylation. *Clin Med.* (2020) 15:3. doi: 10.1186/s13280-020-00285-2
23. He Q, Cheng J, Wang Y. Chronic CaMKII inhibition reverses cardiac function and cardiac reserve in HF mice. *Life Sci.* (2019) 219:122–8. doi: 10.1016/j.lfs.2019.01.010
24. Beckendorf J, van den Hoogenhof MMG, Backs J. Physiological and pathophysiological roles of CaMKII in the heart. *Basic Res Cardiol.* (2018) 113:29. doi: 10.1186/s13054-018-0688-8
25. Hu D, Huang J, Hu S, Zhang Y, Li S, Sun Y, et al. A common variant of RIP3 promoter region is associated with poor prognosis in heart failure patients by influencing SOX17 binding. *J Cell Mol Med.* (2019) 23:5317–28. doi: 10.1111/jcmm.14408
26. Zil M, Stafford N, Prehar S, Baudoin F, Oceandy D, Wang X, et al. Cardiac hypertrophy or failure? – A systematic evaluation of the transverse aortic constriction model in C57BL/6NTac and C57BL/6J substrains. *Curr Res Physiol.* (2019) 1:1–10. doi: 10.1016/j.cjphys.2019.10.001

**AUTHOR CONTRIBUTIONS**

JC and JZ were involved in the conception and design of the work, analysis of data, manuscript drafting, and contributed equally to this work. JQ and XC were involved in the acquisition and analysis of data. WZ and XC were involved in the design of the research report and proofreading of the original manuscript. All authors read and approved the final manuscript submitted for publication.

**FUNDING**

This work was funded by grants (81873470 and 82070418) from the National Natural Science Foundation of China.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.847362/full#supplementary-material
27. Duran J, Nickel L, Estrada M, Backs J, van den Hoogenhof MMG. CaMKIIδ splice variants in the healthy and diseased heart. Front Cell Dev Biol. (2021) 9:644630. doi: 10.3389/fcell.2021.644630
28. Zhe-Wei S, Li-Sha G, Yue-Chun L. The role of necroptosis in cardiovascular disease. Front Pharmacol. (2018) 9:721. doi: 10.3389/fphar.2018.00721
29. Mazurek JA, Jessup M. Understanding heart failure. Heart Fail Clin. (2017) 13:1–19. doi: 10.1016/j.hfc.2016.07.001
30. Shrestha A, Mehdizadeh Gohari I, McClane BA. RIPK1, RIP3, and MLKL contribute to cell death caused by clostridium perfringens enterotoxin. mBio. (2019) 10:e2985–2919. doi: 10.1128/mBio.02985-19
31. Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. (2021) 19:4641–57. doi: 10.1016/j.scib.2021.07.038
32. Jung SE, Kim SW, Moon H, Choi WS, Lim S, et al. MicroRNA-26a/b-5p promotes myocardial infarction-induced cell death by downregulating cytochrome c oxidase 5a. Exp Mol Med. (2021) 53:1332–43. doi: 10.1038/s12276-021-00665-0
33. Samson AL, Zhang Y, Geoghegan ND, Davies KA, Mlodzianoski MJ, et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat Commun. (2020) 11:3151. doi: 10.1038/s41467-020-16887-1
34. Garnish SE, Meng Y, Koide A, Sandow JJ, Denbaum E, Jacobsen AV, et al. Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis. Nat Commun. (2021) 12:2211. doi: 10.1038/s41467-021-22400-z
35. Wang L, Zhou L, Zhou Y, Liu L, Jiang W, Zhang H, et al. Necroptosis in pulmonary diseases: a new therapeutic target. Front Pharmacol. (2021) 12:737129. doi: 10.3389/fphar.2021.737129
36. Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. (2019) 99:1765–817. doi: 10.1152/physrev.00022.2018
37. Crowley LC, Waterhouse NJ. Detecting cleaved caspase-3 in apoptotic cells by flow cytometry [J]. Cold Spring Harb Protoc. (2016) 2016: pdb.prot087312. doi: 10.1101/pdb.prot087312
38. Lossi L, Castagna C, Merighi A. Caspase-3 mediated cell death in the normal development of the mammalian cerebellum. Int J Mol Sci. (2018) 19:3999. doi: 10.3390/ijms19123999
39. Glushakov AO, Glushakova OY, Koroil TY, Acosta SA, Borlongan CV, Valadka AB, et al. Chronic upregulation of cleaved-caspase-3 associated with chronic myelin pathology and microvascular reorganization in the thalamus after traumatic brain injury in rats. Int J Mol Sci. (2018) 19:3151. doi: 10.3390/ijms19103151
40. Zhou M, Liu X, Li Z, Huang Q, Li F, Li CY. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer. (2018) 143:921–30. doi: 10.1002/ijc.31374
41. Yang Y, Jiang K, Liu X, Qin M, Xiang Y. CaMKII in regulation of cell death during myocardial reperfusion injury. Front Mol Biosci. (2021) 8:668129. doi: 10.3389/fmolb.2021.668129
42. Roe ND, Ren J. Oxidative activation of Ca2+/calmodulin-activated kinase II mediates ER stress-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol. (2013) 304:H828–39. doi: 10.1152/ajpheart.00752.2012
43. Federico M, Portiansky EL, Sommese L, Alvarado FJ, Blanco PG, Zanuzi CN, et al. Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance. J Physiol. (2017) 595:4089–108. doi: 10.1113/jp273714
44. Junho CVC, Caio-Silva W, Trentin-Sonoda M, Carneiro-Ramos MS. An overview of the role of calcium/calmodulin-dependent protein kinase in cardiorenal syndrome. Front Physiol. (2020) 11:735. doi: 10.3389/fphys.2020.00735
45. Santamaría PG, Floristan A, Fontanals-Cirera B, Vázquez-Naharro A, Santos V, Morales S, et al. Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability. Cell Death Differ. (2018) 25:935–50. doi: 10.1038/s41418-017-0030-2
46. Zhu P, Hu S, Jin Q, Li D, Tian F, Toan S, et al. Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/XO/ROS/mPTP pathway. Redox Biol. (2018) 16:157–68. doi: 10.1016/j.redox.2018.02.019

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cao, Zhang, Qian, Wang, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.